Phase 1 Evaluation of H1 Influenza Vaccine Delivered by MIMIX MAP

Summary

A Phase 1, Randomized, Rater and Participant Blinded Placebo Controlled Study to Evaluate the Safety, Reactogenicity, Tolerability and Immunogenicity of a Standard and a Fractional Dose of H1 Influenza Vaccine Delivered by VX-103 (a MIMIX Microneedle Array Patch (MAP) System) in Healthy Adults ≥18-39 Years of Age

Timeline

Start

2022-07-02

Primary completion

2023-03-13

Completion

2023-03-13

Publications

• Garg N, Tellier G, Vale N, Kluge J, Portman JL, Markowska A, Tussey L. Phase 1, randomized, rater and participant blinded placebo-controlled study of the safety, reactogenicity, tolerability and immunogenicity of H1N1 influenza vaccine delivered by VX-103 (a MIMIX microneedle patch [MAP] system) in healthy adults. PLoS One. 2024 Jun 6;19(6):e0303450. doi: 10.1371/journal.pone.0303450. eCollection 2024.

Drugs

Indications